SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AtheroGenics, Inc.{AGIX}-nasdaq
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tom pope who wrote (126)10/13/2004 8:05:00 AM
From: rkrw  Read Replies (1) of 332
 
Not meeting statistical significance in the primary endpoint was a kind way of putting it:

<<<In the analysis of all randomized patients, 25 percent of placebo-treated patients achieved an ACR 20 response at Week 12 compared with 20 percent at 75 mg, 15 percent at 150 mg, and 23 percent at 225 mg of AGIX- 4207-treated patients.>>>
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News